## Jing Fu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4260476/publications.pdf

Version: 2024-02-01

687363 794594 21 619 13 19 citations h-index g-index papers 21 21 21 1076 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway. Nature Communications, 2012, 3, 976.	12.8	82
2	PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation. Blood, 2009, 113, 4370-4380.	1.4	75
3	The tumor suppressor gene WWOX links the canonical and noncanonical NF-κB pathways in HTLV-I Tax-mediated tumorigenesis. Blood, 2011, 117, 1652-1661.	1.4	67
4	Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. Journal of Clinical Investigation, 2016, 126, 1759-1772.	8.2	54
5	Epigenetic Repression of PDZ-LIM Domain-containing Protein 2. Journal of Biological Chemistry, 2010, 285, 11786-11792.	3.4	53
6	DNA Methylation–Dependent Repression of PDZ-LIM Domain–Containing Protein 2 in Colon Cancer and Its Role as a Potential Therapeutic Target. Cancer Research, 2010, 70, 1766-1772.	0.9	45
7	NF-κB and cancer: a paradigm of Yin-Yang. American Journal of Cancer Research, 2011, 1, 192-221.	1.4	45
8	Molecular determinants of PDLIM2 in suppressing HTLV-I Tax-mediated tumorigenesis. Oncogene, 2010, 29, 6499-6507.	5.9	35
9	Cerebral Functional Manipulation of Repetitive Transcranial Magnetic Stimulation in Cognitive Impairment Patients After Stroke: An fMRI Study. Frontiers in Neurology, 2020, 11, 977.	2.4	32
10	PDLIM2 restricts Th1 and Th17 differentiation and prevents autoimmune disease. Cell and Bioscience, 2012, 2, 23.	4.8	30
11	Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization. Leukemia, 2013, 27, 1407-1411.	7.2	17
12	Elevated Translation Initiation Factor elF4E Is an Attractive Therapeutic Target in Multiple Myeloma. Molecular Cancer Therapeutics, 2016, 15, 711-719.	4.1	16
13	IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation. Blood Advances, 2018, 2, 492-504.	5.2	15
14	Nuclear protein NP60 regulates p38 MAPK activity. Journal of Cell Science, 2006, 119, 115-123.	2.0	14
15	Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation. Haematologica, 2018, 103, 1688-1697.	3.5	14
16	Inhibition of Inflammation by a p38 MAP Kinase Targeted Cell Permeable Peptide. Medicinal Chemistry, 2008, 4, 597-604.	1.5	10
17	Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma. Blood, 2021, 137, 1754-1764.	1.4	7
18	Carbonic anhydrase 12 gene silencing reverses the sensitivity of paclitaxel in drug-resistant breast cancer cells. Bioengineered, 2021, 12, 9806-9818.	3.2	6

#	Article	IF	CITATIONS
19	Coordination of the canonical and noncanonical IKK/NF- $\hat{l}^{\text{e}}$ B signaling pathways in HTLV-I Tax-mediated tumorigenesis. Retrovirology, 2011, 8, .	2.0	2
20	Inducible Silencing Of eIF4E Using a Tet-On System Results In Myeloma Growth In Vivo That Correlates With eIF4E Expression. Blood, 2013, 122, 3164-3164.	1.4	0
21	Knockdown Of Matrix Metalloproteinase 13 (MMP13) In 5TGM1 Multiple Myeloma Cells Inhibits Development Of Lytic Bone Lesions In Vivo. Blood, 2013, 122, 879-879.	1.4	O